europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

European health community issues key questions Article 50 negotiations must answer for patients and public health

31/03/2018
PRESS RELEASE
IB1

European health community issues key questions Article 50 negotiations must answer for patients and public health

The European Health Community has warned that time is running out to secure patients’ interests in Brexit negotiations. With Phase 2 of the negotiations looming, health groups across Europe have drawn up a list of crucial unanswered questions that must be answered by the EU and UK negotiators to ‘put patients first’ in the negotiations.

These questions were set out at a meeting of a Coalition of Brussels based health stakeholders on 21 February and have been released in advance of the European Council meeting on 22 March, where the guidelines for the negotiation of phase 2 will be agreed. These focus on how to prioritise patient safety and public health in the Article 50 negotiations on the future relationship between the UK and the EU. Each speaker posed three questions of importance which will need resolving for patients.

The Group has now published this document in light of the discussions by the EU27 on the draft guidelines for the future relationship between the UK and EU in the weeks to come.

Some of the key questions the Coalition sets out are:

• How will a trade agreement ensure sufficient and timely supply of medicines and medical devices for both EU and UK patients? • In the event of a ‘no deal’ Brexit, how would EU27 national governments avoid that public health be affected across the EU? • How will the UK and the EU come to an agreement to ensure the future drug licensing system does not exacerbate delays in access to the most innovative treatments for patients, both in the UK and across the EU? • How can EU and UK patients benefit from the pooling of scarce expertise in rare and complex diseases under European Reference Networks?

This follows on from the publication of a policy statement by the same group in December 20171. The document outlined five priorities, which the group says will ‘determine the risk in Brexit’s impact on patients and public health across Europe’.

These priorities are:

• Bring close cooperation between the EU and UK on the regulation of medicines and medical technologies, to ensure that UK and EU patients will continue to have access to life-saving medicines and medical technologies. • Establish a common framework for collaboration in research and information sharing between the EU27 and the UK. • Ensure that there are continued reciprocal healthcare arrangements between the EU and UK. • Develop strong coordination between the EU and UK on public health, including in pandemic preparation and disease prevention programmes. • Ensure EU and UK health professionals continue to benefit from mutually beneficial training and education opportunities, with automatic recognition of qualifications.

Nicola Bedlington, General Secretary, European Patients Forum “Brexit has great implications in various areas, public health, patient safety, access to medicine and medical devices, research and many others. This is so, not only for patients residing in the UK, but also in the rest of the EU(27). When it comes to those areas relevant to healthcare, patients’ interest should be shaping the agenda of both sides of the negotiating parties”



Download the file below to read the full Press Release.

European health community issues key questions Article 50 negotiations must answer for patients and public health


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
17/01/2023

EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more
19/12/2022

EuropaBio sat down with new member Association of Biotechnological Companies Bioforum, to find out how they champion biotech in central and eastern Europe


Read more

Important links

  • EuropaBio launches SME BioForum in Rare Diseases
  • EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform

Categories in our Newsroom

Search by tags

  • Innovation
  • Excellence
  • Science
  • ATMPs
  • Healthcare Biotech
  • Industrial Biotech
  • Investment
  • EuropaBio
  • EFIB
  • Regulation
  • Rare Diseases
  • COVID-19
  • Members
  • Cancer
  • Patients
  • Patient BioForum
  • Gene & Cell Therapies
  • Accessibility
  • Intellectual Property
  • Pharmaceutical Strategy for Europe

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies